Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Prolia and Xgeva just got rivals: FDA clears BILDYOS and BILPREVDA biosimilars for U.S. launch
The FDA has approved Henlius and Organon’s denosumab biosimilars. Find out what this means for U.S. bone health access, pricing, and investor sentiment.
Can High Tide’s Remexian acquisition turn it into a global cannabis leader? €26.4m deal explained
High Tide acquires 51% of Germany's Remexian Pharma for €26.4M with a 5-year full buyout option. Find out how this move expands its global cannabis reach.
Avacta completes Coris sale in final diagnostics exit: Is its precision oncology pivot ready for prime time?
Avacta completes sale of Coris Bioconcept to focus solely on oncology. Find out what this pivot means for its stock, strategy, and pre|CISION® pipeline.
LOTTE BIOLOGICS secures third major contract of 2025 through new U.S. biopharma manufacturing deal
LOTTE BIOLOGICS wins a third U.S. contract in 2025, boosting its CDMO momentum and investor sentiment. Find out how the deal shapes biomanufacturing strategy.
FDA acceptance of Sarfaraz Niazi’s biosimilar petition could reset the economics of monoclonal antibody approvals
FDA accepts Sarfaraz Niazi’s petition to waive costly clinical efficacy studies for monoclonal antibody biosimilars, reshaping drug affordability worldwide.
FDA accepts first biosimilar without clinical efficacy studies: Will this redefine global biologics access?
FDA waives efficacy trials for Stelara biosimilar, opening new doors for fast-track biosimilar access. Find out how this could reshape drug affordability worldwide.
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.
Inside CapVest’s acquisition of STADA: What changes after Bain Capital and Cinven?
CapVest is acquiring majority control of STADA from Bain and Cinven. Find out how this move could reshape the pharma giant’s global growth strategy.
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
AYP-101 could replace Kybella? AMI Pharm’s injectable shows strong Phase 2 results for fat reduction
AMI Pharm's AYP-101 delivers strong Phase 2 results in reducing submental fat—find out why it’s being called a game-changer in nonsurgical aesthetics.